- - |
- -5
100 . 100 8.3 .., 5.3 .. , , .
1 100 - 100 (/). 2 . , 6, . , , , .
21 - 6 3000 19 87 (, ). , ( ) . , , , 1 . , , , : 62% ( 25 ), 74% ( 50 ) 82% ( 100 ), 25% . , , .
.
. 40% (25-63%). In vitro 1.7 / (3.5 ) 5 50%. 100 Cmax 18 / (38 ) 60 (30-120 ).
Vd 105 .
, , CYP3A4 ( ) CYP2C9 ( ).
41 /, T1/2 - 3-5 . , , ( 80% ) - ( 13% ).
( 65 ) , 40% (18-45 ) .
.
25 , - 1 48 .
800 , .
450 - 12, 29, 219, 2D6, 21 34 (K50 >150 ). , .
.
. .
, , .
;
, . (, , ), (- , , ).
, - ( .. , , , , , , ), . , , - . , . .
, , - . , , . ( , ), , .
5, . , () , 50 , , , , . - 5 .
, 5, . . - 5 . .
, , in vitro. , . , , ( 12.9%, 0%), ( 3%, 2.4%). , , (8.8%), , (1.7%).
( 30-80 /) , (<30 /) 25 .
25 .
.
18 .